Skip to main content
Filters

    Results for Activators & Inhibitors ( 70880 )

      • Ref: T37232
        Sizes: 1 mg, 5 mg
        From: €313.00

        (+)-Geodin (Legacy Tebubio ref. 282T37232). (+)-Geodin is a fungal metabolite. It increases the fibrinolytic activity of bovine aortic endothelial cells (BAECs) when used at concentrations ranging from 50 to 150 μM. (+)-Geodin (1-100 μg/ml) also increases 2-deoxyglucose uptake by rat adipocytes.

        Product detail
      • Ref: T37233
        Sizes: 25 μg, 100 μg, 50 μg, 500 μg
        From: €137.00

        (±)14(15)-EpEDE (Legacy Tebubio ref. 282T37233). 8,11,14-Eicosatrienoic acid, also known as dihomo-γ-linolenic acid , is a polyunsaturated fatty acid (PUFA) produced from γ-linolenic acid by the action of fatty acid elongases. It can be metabolized by the cyclooxygenase pathway to produce 1-series prostaglandins (PGs) (e.g., PGE1). (±)14(15)-EpEDE is an EpEDE acid formed from 8,11,14-eicosatrienoic acid. This monoepoxide can be generated from the PUFA, in vitro, by the action of a strong oxidizing agent. Alternatively, this compound may be produced, in vivo, by epoxidation of the PUFA by cytochrome P450 epoxygenases. The biological properties of this compound are poorly understood.

        Product detail
      • Ref: T37234
        Sizes: 25 μg, 100 μg, 50 μg, 500 μg
        From: €137.00

        (±)14(15)-EpETE (Legacy Tebubio ref. 282T37234). EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators. Cytochrome P450 (CYP450) metabolism of polyunsaturated fatty acids, produces epoxides such as (±)14(15)-EpETrE which are prime candidates for the actual active mediator. However, the CYP450 metabolites of eicosapentaenoic acid and docosahexaenoic acid have been little studied relative to arachidonate epoxygenase metabolites. (±)14(15)-EpETE is the ω-3 homolog of 14(15)-EpETrE, derived via epoxidation of the 14,15-double bond of EPA. The EDHF activity of (±)14(15)-EpETE has not yet been determined.

        Product detail
      • Ref: T37236
        Sizes: 25 μg, 100 μg, 50 μg
        From: €299.00

        (±)17(18)-DiHETE (Legacy Tebubio ref. 282T37236). Eicosapentaenoic acid is an ω-3 fatty acid abundantly available in marine organisms. (±)17(18)-DiHETE is one of the major metabolites produced when eicosapentaenoic acid (EPA) is incubated with various rat tissue homogenates or cynomolgus monkey seminal vesicles. The route of production of (±)17(18)-DiHETE likely proceeds through cytochrome P450-catalyzed epoxidation at the ω-3 double bond followed by conversion to the vicinal diols by epoxide hydrolase. EPA is also metabolized preferentially by Gaeumannomyces graminis to (±)17(18)-DiHETE.

        Product detail
      • Ref: T37237
        Sizes: 25 μg, 100 μg, 50 μg
        From: €267.00

        (±)19(20)-DiHDTE (Legacy Tebubio ref. 282T37237). (±)19(20)-DiHDTE is an oxylipin and an oxidative metabolite of docosapentaenoic acid . It is formed via cytochrome P450 (CYP) metabolism of DPA via a (±)19(20)-EpDTE intermediate.

        Product detail
      • Ref: T37238
        Sizes: 25 μg, 100 μg, 50 μg, 500 μg
        From: €112.00

        (±)19(20)-EpDPA (Legacy Tebubio ref. 282T37238). EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators. Cytochrome P450 (CYP450) metabolism of polyunsaturated fatty acids produces epoxides such as (±)14(15)-EpETrE which are prime candidates for the actual active mediator. However, the CYP450 metabolites of eicosapentaenoic acid and docosahexaenoic acid have been little studied relative to arachidonate epoxygenase metabolites. (±)19(20)-EpDPA is a DHA epoxygenase metabolite, derived via epoxidation of the ω-3 double bond of DHA. The EDHF activity of (±)19(20)-EpDPA has not yet been determined. The epoxygenase metabolites of DHA have also been detected in a mouse inflammation model.

        Product detail
      • Ref: T37239
        Sizes: 25 μg, 100 μg, 50 μg
        From: €137.00

        (±)19(20)-EpDTE (Legacy Tebubio ref. 282T37239). (±)19(20)-EpDTE is an oxylipin and an oxidative metabolite of docosapentaenoic acid (DPA), formed via cytochrome P450 (CYP) metabolism. It can be further metabolized to (±)19(20)-DiHDTE by epoxide hydrolase.

        Product detail
      • Ref: T3724
        Sizes: 1 mg, 5 mg, 25 mg, 100 mg, 50 mg, 10 mg, 200 mg, 1 mL * 10 mM (in DMSO)
        From: €176.00

        Rolapitant hydrochloride (Legacy Tebubio ref. 282T3724). Rolapitant (SCH619734) hydrochloride is a potent, selective, long-acting, and orally active neurokinin 1 (NK1) receptor antagonist with a K_i of 0.66 nM, which does not interact with CYP3A4 and demonstrates potent centrally-mediated anti-emetic activity in both acute and delayed ferret emesis models [1] [2].

        Product detail
      • Ref: T37240
        Sizes: 25 μg, 100 μg, 50 μg, 250 μg
        From: €262.00

        (±)4(5)-DiHDPA lactone (Legacy Tebubio ref. 282T37240). (±)5(6)-DiHET lactone is a 1,5 cyclic ester derived from (±)5(6)-DiHET , which, in turn, is a potential derivative of epoxidation of arachidonic acid at the α-5 double bond. (±)4(5)-DiHDPA lactone is a derivative of docosahexaenoic acid that is analogous to (±)5(6)-DiHET lactone. It is the 1,4 cyclic ester derived from (±)4(5)-DiHDPA, which is produced by epoxidation of DHA at the α-4 double bond. Its biological activity is unknown.

        Product detail